These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22483675)

  • 1. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
    van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
    Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
    Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
    Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
    Dirkx ML; van Sörnsen De Koste JR; Senan S
    Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of intensity-modulated radiation therapy as a boost treatment on the lung-dose distributions for non-small-cell lung cancer.
    Choi Y; Kim JK; Lee HS; Hur WJ; Chai GY; Kang KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):683-9. PubMed ID: 15927412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
    Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
    Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
    Meijer G; Steenhuijsen J; Bal M; De Jaeger K; Schuring D; Theuws J
    Radiother Oncol; 2011 Sep; 100(3):396-401. PubMed ID: 21955663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
    Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
    Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
    Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
    Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose.
    Nielsen TB; Hansen O; Schytte T; Brink C
    Acta Oncol; 2014 Jan; 53(1):119-25. PubMed ID: 23627917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
    van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
    Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
    Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
    Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.